Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Cash & Equivalents (2017 - 2025)

Eton Pharmaceuticals' Cash & Equivalents history spans 8 years, with the latest figure at $25.9 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 73.69% to $25.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $25.9 million, a 73.69% increase, with the full-year FY2025 number at $25.9 million, up 73.69% from a year prior.
  • Cash & Equivalents hit $25.9 million in Q4 2025 for Eton Pharmaceuticals, down from $37.1 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for ETON hit a ceiling of $37.1 million in Q3 2025 and a floor of $13.4 million in Q3 2022.
  • Historically, Cash & Equivalents has averaged $20.3 million across 5 years, with a median of $19.0 million in 2024.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 209.72% in 2021 and later tumbled 41.09% in 2022.
  • Tracing ETON's Cash & Equivalents over 5 years: stood at $14.4 million in 2021, then increased by 13.18% to $16.3 million in 2022, then soared by 31.17% to $21.4 million in 2023, then tumbled by 30.17% to $14.9 million in 2024, then surged by 73.69% to $25.9 million in 2025.
  • Business Quant data shows Cash & Equivalents for ETON at $25.9 million in Q4 2025, $37.1 million in Q3 2025, and $25.4 million in Q2 2025.